Skip to main content
HUNAN ER-KANG PHARMACEUTICAL CO.,LTD. logo

HUNAN ER-KANG PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 300267 ISIN · CNE100001781 LEI · 300300TIQAG3VXP0ZY74 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,802 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300267

About HUNAN ER-KANG PHARMACEUTICAL CO.,LTD.

https://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of pharmaceutical excipients, active pharmaceutical ingredients (APIs), and finished dosage forms. The company is a global leader in starch capsule technology, providing high-quality, plant-based alternatives to conventional gelatin capsules. Its extensive product catalog features over 100 varieties of excipients, including pharmaceutical-grade starch and modified starch products. By maintaining an integrated supply chain, the company ensures rigorous quality standards across its production processes. Er-Kang provides essential components for drug formulation and delivery to a global market, emphasizing innovation in material science to enhance pharmaceutical stability and safety. Its operations support a broad spectrum of therapeutic applications through specialized chemical and biological manufacturing capabilities.

Recent filings

Filing Released Lang Actions
湖南启元律师事务所关于湖南尔康制药股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 80% confidence The document is a legal opinion letter regarding the 2025 Annual General Meeting of Hunan Erkang Pharmaceutical Co., Ltd. It details the convening procedures, attendance, and provides full vote counts and percentages on AGM proposals. The primary content is the official shareholder voting results at an AGM, matching the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 97% confidence The document is an announcement of the 2025 annual general meeting (AGM) resolutions of Hunan Erkang Pharmaceuticals, detailing meeting attendance, vote counts, proposal results, and legal opinions. It is clearly a declaration of voting results at a shareholders’ meeting and not the meeting materials themselves or a full report. This aligns with the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-20 Chinese
关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 93% confidence The document is a formal notice to convene the 2025 annual shareholders’ meeting, detailing meeting date, agenda items, voting procedures, proxy forms and instructions for shareholders to vote or appoint proxies. It is prepared to solicit shareholder proxies and provide information for the upcoming AGM. This matches the definition of a Proxy Solicitation & Information Statement (PSI) rather than an earnings release or other financial report.
2026-04-22 Chinese
独立董事2025年度述职报告（蒋悟真）
Governance Information Classification · 80% confidence The document is an Independent Director’s annual performance report (“独立董事述职报告”) covering governance duties, board and committee attendance, internal control review, and related corporate governance activities. It is not announcing a board change (MANG), not a financial report (10-K/IR), nor a proxy solicitation statement (PSI). It primarily details governance practices and the director’s oversight role, fitting the Governance Information category (CGR).
2026-04-22 Chinese
关于举行2025年度业绩网上说明会的通知
Investor Presentation Classification · 90% confidence The document is a notice (“通知”) announcing an upcoming online results explanation meeting for the company’s 2025 annual performance. It is not the report itself (the annual report was already published), nor a transcript or regulatory notice of voting. Instead, it invites investors to a live web presentation of results, fitting the definition of an Investor Presentation (IP).
2026-04-22 Chinese
2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is a standalone audit report issued by an accounting firm on the effectiveness of the company’s internal financial reporting controls for the year ended December 31, 2025, including auditor opinions and responsibilities. This matches the definition of an Audit Report / Information (AR). FY 2025
2026-04-22 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.